Please ensure Javascript is enabled for purposes of website accessibility

Sage Therapeutics Disappoints With Its Q4 Report

By Jim Crumly - Feb 27, 2020 at 11:28AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A revenue miss and a lack of news on its depression drug candidate had shareholders down in the dumps.

Shares of Sage Therapeutics (SAGE 9.42%) tumbled Thursday morning after the company reported slower-than-expected revenue growth for its drug for post-partum depression (PPD), and didn't have anything new to say about its stalled effort to bring its drug for major depressive disorder (MDD) to market.

Revenue from sales of PPD drug Zulresso, which launched last summer, came in at $1.96 million, when analysts were expecting $3.68 million. The company said that it now expects that most sites that will administer the drug will take over nine months to become treatment-ready, and some large hospitals and healthcare systems will take a year or more. Previously, the company had said it expected that it would take six to nine months for sites to become treatment-ready.

Investors are focused on the prospects for Sage's MDD candidate, Zuranolone (SAGE-217), but the company couldn't provide any new reasons for them to be optimistic about its chances of approval. The company's share price was cut in half in December after the potential blockbuster drug failed to hit its primary endpoint in a pivotal trial.

Silhouette of a depressed man.

Image source: Getty Images.

Sage's strategy is to amend three other phase 3 studies to test Zuranolone in higher doses in hopes of getting better results, but when questioned on the conference call, company officials had to admit that they had no real data to prove this would work. Sage expects to meet with the U.S. Food and Drug Administration this quarter to review the drug's path forward.

With a slower sales ramp up for Zulresso ahead, as well as an uncertain future for Zuranolone in the face of potential competition from Axsome Therapeutics (AXSM 8.57%) -- 2019's top-performing biotech stock due to successful clinical results from its own MDD drug -- investors were hoping for better news from Sage Thursday.

Jim Crumly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sage Therapeutics, Inc. Stock Quote
Sage Therapeutics, Inc.
SAGE
$41.95 (9.42%) $3.61
Axsome Therapeutics, Inc. Stock Quote
Axsome Therapeutics, Inc.
AXSM
$43.44 (8.57%) $3.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.